The delayed-emesis syndrome from cisplatin

Phase III evaluation of ondansetron versus placebo

David R. Gandara, Walter H. Harvey, Gregory G. Monaghan, Edith A. Perez, Cathy Stokes, Judy C. Bryson, Andrew L. Finn, Paul J. Hesketh

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

Cisplatin may evoke both an acute emetic response during the first 24 hours following treatment and a less well-recognized syndrome of delayed emesis. While delayed emesis is usually less severe in terms of frequency of vomiting episodes, the problem continues to result in significant morbidity. In comparison with acute emesis, the exact pathogenesis of the delayed emesis syndrome remains unclear. Although a combination of oral metoclopramide and dexamethasone is effective in many patients in preventing delayed emesis, almost 50% continue to experience at least one emetic episode when treated with this regimen. A phase III multicenter study has evaluated oral ondansetron versus placebo in the prevention of the delayed-emesis syndrome in 50 patients during days 2 through 5 following high-dose cisplatin administration. Although the daily rates of complete emetic control, failure, and control of nausea favor ondansetron, this trial is statistically inconclusive in establishing efficacy of ondansetron as a single agent in the prevention of delayed emesis. Ondansetron was well tolerated in the dose and schedule used.

Original languageEnglish (US)
Pages (from-to)67-71
Number of pages5
JournalSeminars in Oncology
Volume19
Issue number4 SUPPL. 10
StatePublished - 1992
Externally publishedYes

Fingerprint

Ondansetron
Cisplatin
Vomiting
Placebos
Emetics
Metoclopramide
Nausea
Dexamethasone
Multicenter Studies
Appointments and Schedules
Morbidity

ASJC Scopus subject areas

  • Oncology

Cite this

Gandara, D. R., Harvey, W. H., Monaghan, G. G., Perez, E. A., Stokes, C., Bryson, J. C., ... Hesketh, P. J. (1992). The delayed-emesis syndrome from cisplatin: Phase III evaluation of ondansetron versus placebo. Seminars in Oncology, 19(4 SUPPL. 10), 67-71.

The delayed-emesis syndrome from cisplatin : Phase III evaluation of ondansetron versus placebo. / Gandara, David R.; Harvey, Walter H.; Monaghan, Gregory G.; Perez, Edith A.; Stokes, Cathy; Bryson, Judy C.; Finn, Andrew L.; Hesketh, Paul J.

In: Seminars in Oncology, Vol. 19, No. 4 SUPPL. 10, 1992, p. 67-71.

Research output: Contribution to journalArticle

Gandara, DR, Harvey, WH, Monaghan, GG, Perez, EA, Stokes, C, Bryson, JC, Finn, AL & Hesketh, PJ 1992, 'The delayed-emesis syndrome from cisplatin: Phase III evaluation of ondansetron versus placebo', Seminars in Oncology, vol. 19, no. 4 SUPPL. 10, pp. 67-71.
Gandara DR, Harvey WH, Monaghan GG, Perez EA, Stokes C, Bryson JC et al. The delayed-emesis syndrome from cisplatin: Phase III evaluation of ondansetron versus placebo. Seminars in Oncology. 1992;19(4 SUPPL. 10):67-71.
Gandara, David R. ; Harvey, Walter H. ; Monaghan, Gregory G. ; Perez, Edith A. ; Stokes, Cathy ; Bryson, Judy C. ; Finn, Andrew L. ; Hesketh, Paul J. / The delayed-emesis syndrome from cisplatin : Phase III evaluation of ondansetron versus placebo. In: Seminars in Oncology. 1992 ; Vol. 19, No. 4 SUPPL. 10. pp. 67-71.
@article{13c67267bdd94ff6aae51e08515260f2,
title = "The delayed-emesis syndrome from cisplatin: Phase III evaluation of ondansetron versus placebo",
abstract = "Cisplatin may evoke both an acute emetic response during the first 24 hours following treatment and a less well-recognized syndrome of delayed emesis. While delayed emesis is usually less severe in terms of frequency of vomiting episodes, the problem continues to result in significant morbidity. In comparison with acute emesis, the exact pathogenesis of the delayed emesis syndrome remains unclear. Although a combination of oral metoclopramide and dexamethasone is effective in many patients in preventing delayed emesis, almost 50{\%} continue to experience at least one emetic episode when treated with this regimen. A phase III multicenter study has evaluated oral ondansetron versus placebo in the prevention of the delayed-emesis syndrome in 50 patients during days 2 through 5 following high-dose cisplatin administration. Although the daily rates of complete emetic control, failure, and control of nausea favor ondansetron, this trial is statistically inconclusive in establishing efficacy of ondansetron as a single agent in the prevention of delayed emesis. Ondansetron was well tolerated in the dose and schedule used.",
author = "Gandara, {David R.} and Harvey, {Walter H.} and Monaghan, {Gregory G.} and Perez, {Edith A.} and Cathy Stokes and Bryson, {Judy C.} and Finn, {Andrew L.} and Hesketh, {Paul J.}",
year = "1992",
language = "English (US)",
volume = "19",
pages = "67--71",
journal = "Seminars in Oncology",
issn = "0093-7754",
publisher = "W.B. Saunders Ltd",
number = "4 SUPPL. 10",

}

TY - JOUR

T1 - The delayed-emesis syndrome from cisplatin

T2 - Phase III evaluation of ondansetron versus placebo

AU - Gandara, David R.

AU - Harvey, Walter H.

AU - Monaghan, Gregory G.

AU - Perez, Edith A.

AU - Stokes, Cathy

AU - Bryson, Judy C.

AU - Finn, Andrew L.

AU - Hesketh, Paul J.

PY - 1992

Y1 - 1992

N2 - Cisplatin may evoke both an acute emetic response during the first 24 hours following treatment and a less well-recognized syndrome of delayed emesis. While delayed emesis is usually less severe in terms of frequency of vomiting episodes, the problem continues to result in significant morbidity. In comparison with acute emesis, the exact pathogenesis of the delayed emesis syndrome remains unclear. Although a combination of oral metoclopramide and dexamethasone is effective in many patients in preventing delayed emesis, almost 50% continue to experience at least one emetic episode when treated with this regimen. A phase III multicenter study has evaluated oral ondansetron versus placebo in the prevention of the delayed-emesis syndrome in 50 patients during days 2 through 5 following high-dose cisplatin administration. Although the daily rates of complete emetic control, failure, and control of nausea favor ondansetron, this trial is statistically inconclusive in establishing efficacy of ondansetron as a single agent in the prevention of delayed emesis. Ondansetron was well tolerated in the dose and schedule used.

AB - Cisplatin may evoke both an acute emetic response during the first 24 hours following treatment and a less well-recognized syndrome of delayed emesis. While delayed emesis is usually less severe in terms of frequency of vomiting episodes, the problem continues to result in significant morbidity. In comparison with acute emesis, the exact pathogenesis of the delayed emesis syndrome remains unclear. Although a combination of oral metoclopramide and dexamethasone is effective in many patients in preventing delayed emesis, almost 50% continue to experience at least one emetic episode when treated with this regimen. A phase III multicenter study has evaluated oral ondansetron versus placebo in the prevention of the delayed-emesis syndrome in 50 patients during days 2 through 5 following high-dose cisplatin administration. Although the daily rates of complete emetic control, failure, and control of nausea favor ondansetron, this trial is statistically inconclusive in establishing efficacy of ondansetron as a single agent in the prevention of delayed emesis. Ondansetron was well tolerated in the dose and schedule used.

UR - http://www.scopus.com/inward/record.url?scp=0026808951&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026808951&partnerID=8YFLogxK

M3 - Article

VL - 19

SP - 67

EP - 71

JO - Seminars in Oncology

JF - Seminars in Oncology

SN - 0093-7754

IS - 4 SUPPL. 10

ER -